Telangana: Aurobindo Pharma has announced that the Company will be investing Rs.10.40 crores to acquire 26 percent equity and ...

Ahead of earnings announcement, shares of Aurobindo Pharma ended the trading session flat at ₹1,184.50 apiece on the BSE, ...

Aurobindo Pharma on Thursday reported a 10 per cent year-on-year (Y-o-Y) drop in consolidated profit after tax (PAT) for the ...

Aurobindo Pharma’s Q3 net profit declined 10% YoY to Rs 846 crore, despite record revenue of Rs 7,979 crore. US sales ...

The Hyderabad-based bulk and generic drug maker's net profit fell 9.7% year-on-year to Rs 846 crore in the quarter ended Dec.

Aurobindo Pharma reported a 10% YoY decline in net profit to Rs 846 crore for Q3FY25, mainly due to a decrease in US sales.

HYDERABAD: Degrowth in its US formulations business dragged down Aurobindo Pharma’s consolidated net profits for the third ...

Hyderabad: Degrowth in its US formulations business dragged down Aurobindo Pharma's consolidated net profits for the third ...

Six leading pharmaceutical companies, Sun Pharmaceutical Industries, Ipca Laboratories, Indoco Remedies, Aurobindo Pharma, ...

Indian drugmaker Aurobindo Pharma reported a lower third-quarter profit on Thursday, as a spike in expenses more than offset strong demand for its generic drugs.

周四，里昂证券 (CLSA)分析师将Aurobindo Pharma (ARBP:IN)的股票评级从"持有"上调至"跑赢大市"，尽管将目标价从1,540印度卢比下调至1,400印度卢比。这一修订反映了估值方法的调整，该公司现在采用19倍市盈率 (PE)倍数，低于此前的20倍。这一调整归因于对2027财年盈利预期的下调。